Ecto-F1-ATPase/P2Y pathways in metabolic and vascular functions of high density lipoproteins

Atherosclerosis

Volumn 238, Issue 1, 2015, Pages 89-100

  Martinez, Laurent O ^a,b,c   Najib, Souad ^a,b   Perret, Bertrand ^a,b,c   Cabou, Cendrine ^a,b   Lichtenstein, Laeticia ^a,b  

^a University Hospital of Toulouse   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

^c TOULOUSE UNIVERSITY HOSPITAL   (France)

Author keywords

Apolipoprotein A I; ATP synthase; Bile acids; Endothelial protection; High density lipoprotein; Purinergic receptor

Indexed keywords

APOLIPOPROTEIN A1; CHOLESTEROL; ECTO F 1 ADENOSINE TRIPHOSPHATASE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HIGH DENSITY LIPOPROTEIN RECEPTOR; PURINERGIC P2Y13 RECEPTOR; UNCLASSIFIED DRUG; ADENOSINE TRIPHOSPHATASE; BILE ACID; ECTOATPASE; ENZYME INHIBITOR; PURINERGIC P2Y RECEPTOR;

ADIPOSE TISSUE; ANGIOGENESIS; ATHEROSCLEROSIS; BLOOD VESSEL FUNCTION; CARDIOVASCULAR RISK; CELL SURVIVAL; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; DISEASE MODEL; ENDOCYTOSIS; ENDOTHELIUM; ENDOTHELIUM CELL; ENZYME ACTIVITY; HUMAN; ISCHEMIC HEART DISEASE; LIVER CELL; METABOLISM; NERVE CELL; NONHUMAN; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; TRANSCYTOSIS; TUMOR IMMUNITY; ANIMAL; BIOLOGICAL MODEL; CHEMISTRY; CORONARY ARTERY DISEASE; CYTOLOGY; MOUSE;

ADENOSINE TRIPHOSPHATASES; ANIMALS; APOLIPOPROTEIN A-I; ATHEROSCLEROSIS; BILE ACIDS AND SALTS; CELL SURVIVAL; CHOLESTEROL; CHOLESTEROL, HDL; CORONARY DISEASE; ENDOCYTOSIS; ENDOTHELIAL CELLS; ENZYME INHIBITORS; HEPATOCYTES; HUMANS; LIPOPROTEINS, HDL; MICE; MODELS, BIOLOGICAL; RECEPTORS, PURINERGIC P2Y;

EID: 84912076009     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.11.017     Document Type: Review

References (123)

1. Röhrl C., Stangl H. HDL endocytosis and resecretion. Biochim. Biophys. Acta 2013, 1831:1626-1633.
2. Schwartz C.C., Halloran L.G., Vlahcevic Z.R., Gregory D.H., Swell L. Preferential utilization of free cholesterol from high-density lipoproteins for biliary cholesterol secretion in man. Science 1978, 200:62-64.
3. Robins S.J., Fasulo J.M. High density lipoproteins, but not other lipoproteins, provide a vehicle for sterol transport to bile. J.Clin. Invest 1997, 99:380-384.
4. Acton S., Rigotti A., Landschulz K.T., Xu S., Hobbs H.H., Krieger M. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science 1996, 271:518-520.
5. Gillotte-Taylor K., Boullier A., Witztum J.L., Steinberg D., Quehenberger O. Scavenger receptor class B type I as a receptor for oxidized low density lipoprotein. J.Lipid Res. 2001, 42:1474-1482.
6. Stangl H., Hyatt M., Hobbs H.H. Transport of lipids from high and low density lipoproteins via scavenger receptor-BI. J.Biol. Chem. 1999, 274:32692-32698.
7. Swarnakar S., Temel R.E., Connelly M.A., Azhar S., Williams D.L. Scavenger receptor class B, type I, mediates selective uptake of low density lipoprotein cholesteryl ester. J.Biol. Chem. 1999, 274:29733-29739.
8. Mineo C., Shaul P.W. Functions of scavenger receptor class B, type I in atherosclerosis. Curr. Opin. Lipidol. 2012, 23:487-493.
9. Huby T., Doucet C., Dachet C., Ouzilleau B., Ueda Y., Afzal V., et al. Knockdown expression and hepatic deficiency reveal an atheroprotective role for SR-BI in liver and peripheral tissues. J.Clin. Invest 2006, 116:2767-2776.
10. Silver D.L., Wang N., Xiao X., Tall A.R. High density lipoprotein (HDL) particle uptake mediated by scavenger receptor class b type 1 results in selective sorting of HDL cholesterol from protein and polarized cholesterol secretion. J.Biol. Chem. 2001, 276:25287-25293.
11. Nieland T.J.F., Ehrlich M., Krieger M., Kirchhausen T. Endocytosis is not required for the selective lipid uptake mediated by murine SR-BI. Biochim. Biophys. Acta 2005, 1734:44-51.
12. Harder C.J., Vassiliou G., McBride H.M., McPherson R. Hepatic SR-BI-mediated cholesteryl ester selective uptake occurs with unaltered efficiency in the absence of cellular energy. J.Lipid Res. 2006, 47:492-503.
13. Morrison J.R., McPherson G.A., Fidge N.H. Evidence for two sites on rat liver plasma membranes which interact with high density lipoprotein. J.Biol. Chem. 1992, 267:13205-13209.
14. Martinez L.O., Georgeaud V., Rolland C., Collet X., Tercé F., Perret B., et al. Characterization of two high-density lipoprotein binding sites on porcine hepatocyte plasma membranes: contribution of scavenger receptor class B type I (SR-BI) to the low-affinity component. Biochemistry 2000, 39:1076-1082.
15. Barbaras R., Collet X., Chap H., Perret B. Specific binding of free apolipoprotein A-I to a high-affinity binding site on HepG2 cells: characterization of two high-density lipoprotein sites. Biochemistry 1994, 33:2335-2340.
16. Xu S., Laccotripe M., Huang X., Rigotti A., Zannis V.I., Krieger M. Apolipoproteins of HDL can directly mediate binding to the scavenger receptor SR-BI, an HDL receptor that mediates selective lipid uptake. J.Lipid Res. 1997, 38:1289-1298.
17. Liadaki K.N., Liu T., Xu S., Ishida B.Y., Duchateaux P.N., Krieger J.P., et al. Binding of high density lipoprotein (HDL) and discoidal reconstituted HDL to the HDL receptor scavenger receptor class B type I. Effect of lipid association and APOA-I mutations on receptor binding. J.Biol. Chem. 2000, 275:21262-21271.
18. Thuahnai S.T., Lund-Katz S., Anantharamaiah G.M., Williams D.L., Phillips M.C. Aquantitative analysis of apolipoprotein binding to SR-BI: multiple binding sites for lipid-free and lipid-associated apolipoproteins. J.Lipid Res. 2003, 44:1132-1142.
19. Guendouzi K., Jaspard B., Barbaras R., Motta C., Vieu C., Marcel Y., et al. Biochemical and physical properties of remnant-HDL2 and of pre beta 1-HDL produced by hepatic lipase. Biochemistry 1999, 38:2762-2768.
20. Guendouzi K., Collet X., Perret B., Chap H., Barbaras R. Remnant high density lipoprotein2 particles produced by hepatic lipase display high-affinity binding and increased endocytosis into a human hepatoma cell line (HEPG2). Biochemistry 1998, 37:14974-14980.
21. Martinez L.O., Jacquet S., Esteve J.P., Rolland C., Cabezon E., Champagne E., et al. Ectopic beta-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis. Nature 2003, 421:75-79.
22. Boyer P.D. The ATP synthase - a splendid molecular machine. Annu. Rev. Biochem. 1997, 66:717-749.
23. Stock D., Leslie A.G., Walker J.E. Molecular architecture of the rotary motor in ATP synthase. Science 1999, 286:1700-1705.
24. Pullman M.E., Monroy G.C. Anaturally occurring inhibitor of mitochondrial adenosine triphosphatase. J.Biol. Chem. 1963, 238:3762-3769.
25. Cabezon E., Montgomery M.G., Leslie A.G., Walker J.E. The structure of bovine F1-ATPase in complex with its regulatory protein IF1. Nat. Struct. Biol. 2003, 10:744-750.
26. Faccenda D., Campanella M. Molecular regulation of the mitochondrial F(1)F(o)-ATPsynthase: physiological and pathological significance of the inhibitory factor 1 (IF(1)). Int. J. Cell. Biol. 2012, 2012:367934.
27. Jacquet S., Malaval C., Martinez L.O., Sak K., Rolland C., Perez C., et al. The nucleotide receptor P2Y13 is a key regulator of hepatic high-density lipoprotein (HDL) endocytosis. Cell. Mol. Life Sci. 2005, 62:2508-2515.
28. Fabre A.C., Vantourout P., Champagne E., Terce F., Rolland C., Perret B., et al. Cell surface adenylate kinase activity regulates the F(1)-ATPase/P2Y (13)-mediated HDL endocytosis pathway on human hepatocytes. Cell. Mol. Life Sci. 2006, 63:2829-2837.
29. Beisiegel U., Weber W., Havinga J.R., Ihrke G., Hui D.Y., Wernette-Hammond M.E., et al. Apolipoprotein E-binding proteins isolated from dog and human liver. Arteriosclerosis 1988, 8:288-297.
30. Mahley R.W., Hui D.Y., Innerarity T.L., Beisiegel U. Chylomicron remnant metabolism. Role of hepatic lipoprotein receptors in mediating uptake. Arteriosclerosis 1989, 9:I14-I18.
31. Mangiullo R., Gnoni A., Leone A., Gnoni G.V., Papa S., Zanotti F. Structural and functional characterization of F(o)F(1)-ATP synthase on the extracellular surface of rat hepatocytes. Biochim. Biophys. Acta 2008, 1777:1326-1335.
32. Ralevic V., Burnstock G. Receptors for purines and pyrimidines. Pharmacol. Rev. 1998, 50:413-492.
33. Roman R.M., Wang Y., Lidofsky S.D., Feranchak A.P., Lomri N., Scharschmidt B.F., et al. Hepatocellular ATP-binding cassette protein expression enhances ATP release and autocrine regulation of cell volume. J.Biol. Chem. 1997, 272:21970-21976.
34. Okada S.F., O'Neal W.K., Huang P., Nicholas R.A., Ostrowski L.E., Craigen W.J., et al. Voltage-dependent anion channel-1 (VDAC-1) contributes to ATP release and cell volume regulation in murine cells. J.Gen. Physiol. 2004, 124:513-526.
35. Lazarowski E.R., Boucher R.C., Harden T.K. Mechanisms of release of nucleotides and integration of their action as P2X- and P2Y-receptor activating molecules. Mol. Pharmacol. 2003, 64:785-795.
36. Lazarowski E.R., Boucher R.C., Harden T.K. Constitutive release of ATP and evidence for major contribution of ecto-nucleotide pyrophosphatase and nucleoside diphosphokinase to extracellular nucleotide concentrations. J.Biol. Chem. 2000, 275:31061-31068.
37. Beaudoin A.R., Grondin G., Gendron F.P. Immunolocalization of ATP diphosphohydrolase in pig and mouse brains, and sensory organs of the mouse. Prog. Brain Res. 1999, 120:387-395.
38. Jacobson K.A., Boeynaems J.M. P2Y nucleotide receptors: promise of therapeutic applications. Drug Discov. Today 2010, 15:570-578.
39. Boeynaems J.-M., Communi D., Robaye B. Overview of the pharmacology and physiological roles of P2Y receptors. Wiley Interdiscip. Rev. Membr. Transp. Signal 2012, 1:581-588.
40. Gachet C. ADP receptors of platelets and their inhibition. Thromb. Haemost. 2001, 86:222-232.
41. Communi D., Gonzalez N.S., Detheux M., Brezillon S., Lannoy V., Parmentier M., et al. Identification of a novel human ADP receptor coupled to G(i). J.Biol. Chem. 2001, 276:41479-41485.
42. Malaval C., Laffargue M., Barbaras R., Rolland C., Peres C., Champagne E., et al. RhoA/ROCK I signalling downstream of the P2Y13 ADP-receptor controls HDL endocytosis in human hepatocytes. Cell. Signal 2009, 21:120-127.
43. Rai A.K., Spolaore B., Harris D.A., Dabbeni-Sala F., Lippe G. Ectopic F0F 1 ATP synthase contains both nuclear and mitochondrially-encoded subunits. J.Bioenerg. Biomembr. 2013, 45:569-579.
44. Schmidt C., Lepsverdize E., Chi S.L., Das A.M., Pizzo S.V., Dityatev A., et al. Amyloid precursor protein and amyloid beta-peptide bind to ATP synthase and regulate its activity at the surface of neural cells. Mol. Psychiatry 2008, 13:953-969.
45. Neuspiel M., Schauss A.C., Braschi E., Zunino R., Rippstein P., Rachubinski R.A., et al. Cargo-selected transport from the mitochondria to peroxisomes is mediated by vesicular carriers. Curr. Biol. 2008, 18:102-108.
46. Braschi E., Goyon V., Zunino R., Mohanty A., Xu L., McBride H.M. Vps35 mediates vesicle transport between the mitochondria and peroxisomes. Curr. Biol. 2010, 20:1310-1315.
47. Soubannier V., McLelland G.-L., Zunino R., Braschi E., Rippstein P., Fon E.A., et al. Avesicular transport pathway shuttles cargo from mitochondria to lysosomes. Curr. Biol. 2012, 22:135-141.
48. Yonally S.K., Capaldi R.A. The F(1)F(0) ATP synthase and mitochondrial respiratory chain complexes are present on the plasma membrane of an osteosarcoma cell line: an immunocytochemical study. Mitochondrion 2006, 6:305-314.
49. Zhang L.H., Kamanna V.S., Zhang M.C., Kashyap M.L. Niacin inhibits surface expression of ATP synthase beta chain in HepG2 cells: implications for raising HDL. J.Lipid Res. 2008, 49:1195-1201.
50. Verdier C., Martinez L.O., Ferrières J., Elbaz M., Genoux A., Perret B. Targeting high-density lipoproteins: update on a promising therapy. Arch. Cardiovasc. Dis. 2013, 106:601-611.
51. Pons V., Serhan N., Gayral S., Malaval C., Nauze M., Malet N., et al. Role of the ubiquitin-proteasome system in the regulation of P2Y13 receptor expression: impact on hepatic HDL uptake. Cell. Mol. Life Sci. 2014, 71:1775-1788.
52. Goffinet M., Tardy C., Boubekeur N., Cholez G., Bluteau A., Oniciu D.C., et al. P2Y13 receptor regulates HDL metabolism and atherosclerosis invivo. PLoS One 2014, 9:e95807.
53. Fabre A.C.C., Malaval C., Ben Addi A., Verdier C., Pons V., Serhan N., et al. P2Y13 receptor is critical for reverse cholesterol transport. Hepatology 2010, 52:1477-1483.
54. Serhan N., Cabou C., Verdier C., Lichtenstein L., Malet N., Perret B., et al. Chronic pharmacological activation of P2Y13 receptor in mice decreases HDL-cholesterol level by increasing hepatic HDL uptake and bile acid secretion. Biochim. Biophys. Acta 2013, 1831:719-725.
55. Bravo I., Amigo L., Cohen D.E., Nervi F., Rigotti A., Francone O., et al. Role of plasma and liver cholesterol- and lipoprotein-metabolism determinants in LpX formation in the mouse. Biochim. Biophys. Acta 2007, 1770:979-988.
56. Giorgio V., Bisetto E., Franca R., Harris D.A., Passamonti S., Lippe G. The ectopic F(O)F(1) ATP synthase of rat liver is modulated in acute cholestasis by the inhibitor protein IF1. J.Bioenerg. Biomembr. 2010, 42:117-123.
57. Song K., Han Y., Zhang L., Liu G., Yang P., Cheng X., et al. ATP synthase β-chain overexpression in SR-BI knockout mice increases HDL uptake and reduces plasma HDL level. Int. J. Endocrinol. 2014, 2014:356432.
58. Blom D., Yamin T.-T.T., Champy M.-F.F., Selloum M., Bedu E., Carballo-Jane E., et al. Altered lipoprotein metabolism in P2Y(13) knockout mice. Biochim. Biophys. Acta 2010, 1801:1349-1360.
59. Lichtenstein L., Serhan N., Annema W., Combes G., Robaye B., Boeynaems J.-M., et al. Lack of P2Y13 in mice fed a high cholesterol diet results in decreased hepatic cholesterol content, biliary lipid secretion and reverse cholesterol transport. Nutr. Metab. (Lond) 2013, 10:67.
60. Timmins J.M., Lee J.Y., Boudyguina E., Kluckman K.D., Brunham L.R., Mulya A., et al. Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. J.Clin. Invest 2005, 115:1333-1342.
61. Wiersma H., Nijstad N., de Boer J.F., Out R., Hogewerf W., Van Berkel T.J., et al. Lack of Abcg1 results in decreased plasma HDL cholesterol levels and increased biliary cholesterol secretion in mice fed a high cholesterol diet. Atherosclerosis 2009, 206:141-147.
62. Basso F., Freeman L., Knapper C.L., Remaley A., Stonik J., Neufeld E.B., et al. Role of the hepatic ABCA1 transporter in modulating intrahepatic cholesterol and plasma HDL cholesterol concentrations. J.Lipid Res. 2003, 44:296-302.
63. Haghpassand M., Bourassa P.A., Francone O.L., Aiello R.J. Monocyte/macrophage expression of ABCA1 has minimal contribution to plasma HDL levels. J.Clin. Invest 2001, 108:1315-1320.
64. Annema W., Tietge U.J. Regulation of reverse cholesterol transport - a comprehensive appraisal of available animal studies. Nutr. Metab. (Lond.) 2012, 9.
65. Zhao Y., Pennings M., Vrins C.L., Calpe-Berdiel L., Hoekstra M., Kruijt J.K., et al. Hypocholesterolemia, foam cell accumulation, but no atherosclerosis in mice lacking ABC-transporter A1 and scavenger receptor BI. Atherosclerosis 2011, 218:314-322.
66. Green D.W., Grover G.J. The IF(1) inhibitor protein of the mitochondrial F(1)F(0)-ATPase. Biochim. Biophys. Acta 2000, 1458:343-355.
67. Genoux A., Pons V., Radojkovic C., Roux-Dalvai F., Combes G., Rolland C., et al. Mitochondrial inhibitory factor 1 (IF1) is present in human serum and is positively correlated with HDL-cholesterol. PLoS One 2011, 6:e23949.
68. Genoux A., Ruidavets J.-B.B., Ferrières J., Combes G., Lichtenstein L., Pons V., et al. Serum IF1 concentration is independently associated to HDL levels and to coronary heart disease: the GENES study. J.Lipid Res. 2013, 54:2550-2558.
69. Camont L., Chapman M.J., Kontush A. Biological activities of HDL subpopulations and their relevance to cardiovascular disease. Trends Mol. Med. 2011, 17:594-603.
70. Zhong S., Sharp D.S., Grove J.S., Bruce C., Yano K., Curb J.D., et al. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J.Clin. Invest 1996, 97:2917-2923.
71. Cortes-Hernandez P., Dominguez-Ramirez L., Estrada-Bernal A., Montes-Sanchez D.G., Zentella-Dehesa A., de Gomez-Puyou M.T., et al. The inhibitor protein of the F1F0-ATP synthase is associated to the external surface of endothelial cells. Biochem. Biophys. Res. Commun. 2005, 330:844-849.
72. Contessi S., Comelli M., Cmet S., Lippe G., Mavelli I. IF(1) distribution in HepG2 cells in relation to ecto-F(0)F (1)ATPsynthase and calmodulin. J.Bioenerg. Biomembr. 2007, 39:291-300.
73. Radojkovic C., Genoux A., Pons V., Combes G., de Jonge H., Champagne E., et al. Stimulation of cell surface F1-ATPase activity by apolipoprotein A-I inhibits endothelial cell apoptosis and promotes proliferation. Arterioscler. Thromb. Vasc. Biol. 2009, 29:1125-1130.
74. Hassinen I.E., Vuorinen K.H., Ylitalo K., Ala-Rämi A. Role of cellular energetics in ischemia-reperfusion and ischemic preconditioning of myocardium. Mol. Cell. Biochem. 1998, 184:393-400.
75. Penna C., Pagliaro P., Rastaldo R., Di Pancrazio F., Lippe G., Gattullo D., et al. F0F1 ATP synthase activity is differently modulated by coronary reactive hyperemia before and after ischemic preconditioning in the goat. Am. J. Physiol. Heart Circ. Physiol. 2004, 287:H2192-H2200.
76. Tran-Dinh A., Diallo D., Delbosc S., Varela-Perez L.M., Dang Q.B., Lapergue B., et al. HDL and endothelial protection. Br. J. Pharmacol. 2013, 169:493-511.
77. Mineo C., Deguchi H., Griffin J.H., Shaul P.W. Endothelial and antithrombotic actions of HDL. Circ. Res. 2006, 98:1352-1364.
78. Moser T.L., Stack M.S., Asplin I., Enghild J.J., Hojrup P., Everitt L., et al. Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc. Natl. Acad. Sci. U S A 1999, 96:2811-2816.
79. Cavelier C., Ohnsorg P.M., Rohrer L., von Eckardstein A. The beta-chain of cell surface F0F1 ATPase modulates ApoA-I and HDL transcytosis through aortic endothelial cells. Arterioscler. Thromb. Vasc. Biol. 2012, 32:131-139.
80. Quillen E.E., Haslam G.C., Samra H.S., Amani-Taleshi D., Knight J.A., Wyatt D.E., et al. Ectoadenylate kinase and plasma membrane ATP synthase activities of human vascular endothelial cells. J.Biol. Chem. 2006, 281:20728-20737.
81. González-Pecchi V., Valdés S., Pons V., Honorato P., Martinez L.O., Lamperti L., et al. Apolipoprotein A-I enhances proliferation of human endothelial progenitor cells and promotes angiogenesis through the cell surface ATP synthase. Microvasc. Res. 2015, 98:9-15.
82. Seetharam D., Mineo C., Gormley A.K., Gibson L.L., Vongpatanasin W., Chambliss K.L., et al. High-density lipoprotein promotes endothelial cell migration and reendothelialization via scavenger receptor-B type I. Circ. Res. 2006, 98:63-72.
83. Xue J., Wei J., Dong X., Zhu C., Li Y., Song A., et al. ABCG1 deficiency promotes endothelial apoptosis by endoplasmic reticulum stress-dependent pathway. J.Physiol. Sci. 2013, 63:435-444.
84. Nofer J.R., Levkau B., Wolinska I., Junker R., Fobker M., von Eckardstein A., et al. Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-associated lysosphingolipids. J.Biol. Chem. 2001, 276:34480-34485.
85. Kimura T., Sato K., Malchinkhuu E., Tomura H., Tamama K., Kuwabara A., et al. High-density lipoprotein stimulates endothelial cell migration and survival through sphingosine 1-phosphate and its receptors. Arterioscler. Thromb. Vasc. Biol. 2003, 23:1283-1288.
86. Jaspard B., Fournier N., Vieitez G., Atger V., Barbaras R., Vieu C., et al. Structural and functional comparison of HDL from homologous human plasma and follicular fluid. A model for extravascular fluid. Arterioscler. Thromb. Vasc. Biol. 1997, 17:1605-1613.
87. Rye K.A., Barter P.J. Formation and metabolism of prebeta-migrating, lipid-poor apolipoprotein A-I. Arterioscler. Thromb. Vasc. Biol. 2003, 24:421-428.
88. Rohrer L., Cavelier C., Fuchs S., Schluter M.A., Volker W., von Eckardstein A. Binding, internalization and transport of apolipoprotein A-I by vascular endothelial cells. Biochim. Biophys. Acta 2006, 1761:186-194.
89. Cavelier C., Rohrer L., von Eckardstein A. ATP-Binding cassette transporter A1 modulates apolipoprotein A-I transcytosis through aortic endothelial cells. Circ. Res. 2006, 99:1060-1066.
90. Rohrer L., Ohnsorg P.M., Lehner M., Landolt F., Rinninger F., von Eckardstein A. High-density lipoprotein transport through aortic endothelial cells involves scavenger receptor BI and ATP-binding cassette transporter G1. Circ. Res. 2009, 104:1142-1150.
91. Schreibman P.H., Dell R.B. Human adipocyte cholesterol. Concentration, localization, synthesis, and turnover. J.Clin. Invest 1975, 55:986-993.
92. Yvan-Charvet L., Bobard A., Bossard P., Massiéra F., Rousset X., Ailhaud G., et al. Invivo evidence for a role of adipose tissue SR-BI in the nutritional and hormonal regulation of adiposity and cholesterol homeostasis. Arterioscler. Thromb. Vasc. Biol. 2007, 27:1340-1345.
93. Chung S., Sawyer J.K., Gebre A.K., Maeda N., Parks J.S. Adipose tissue ATP binding cassette transporter A1 contributes to high-density lipoprotein biogenesis invivo. Circulation 2011, 124:1663-1672.
94. Howard A.D., Verghese P.B., Arrese E.L., Soulages J.L. Characterization of apoA-I-dependent lipid efflux from adipocytes and role of ABCA1. Mol. Cell. Biochem. 2010, 343:115-124.
95. Arakaki N., Kita T., Shibata H., Higuti T. Cell-surface H+-ATP synthase as a potential molecular target for anti-obesity drugs. FEBS Lett. 2007, 581:3405-3409.
96. Howard A.D., Verghese P.B., Arrese E.L., Soulages J.L. The beta-subunit of ATP synthase is involved in cellular uptake and resecretion of apoA-I but does not control apoA-I-induced lipid efflux in adipocytes. Mol. Cell. Biochem. 2011, 348:155-164.
97. Lyly A., Marjavaara S.K., Kyttala A., Uusi-Rauva K., Luiro K., Kopra O., et al. Deficiency of the INCL protein Ppt1 results in changes in ectopic F1-ATP synthase and altered cholesterol metabolism. Hum. Mol. Genet. 2008, 17:1406-1417.
98. Moser T.L., Kenan D.J., Ashley T.A., Roy J.A., Goodman M.D., Misra U.K., et al. Endothelial cell surface F1-FO ATP synthase is active in ATP synthesis and is inhibited by angiostatin. Proc. Natl. Acad. Sci. U S A 2001, 98:6656-6661.
99. Chi S.L., Pizzo S.V. Angiostatin is directly cytotoxic to tumor cells at low extracellular pH: a mechanism dependent on cell surface-associated ATP synthase. Cancer Res. 2006, 66:875-882.
100. Vantourout P., Radojkovic C., Lichtenstein L., Pons V., Champagne E., Martinez L.O. Ecto-F(1)-ATPase: a moonlighting protein complex and an unexpected apoA-I receptor. World J. Gastroenterol. 2010, 16:5925-5935.
101. Constant P., Davodeau F., Peyrat M.A., Poquet Y., Puzo G., Bonneville M., et al. Stimulation of human gamma delta T cells by nonpeptidic mycobacterial ligands. Science 1994, 264:267-270.
102. Gober H.-J., Kistowska M., Angman L., Jenö P., Mori L., De Libero G. Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. J.Exp. Med. 2003, 197:163-168.
103. Mookerjee-Basu J., Vantourout P., Martinez L.O., Perret B., Collet X., Perigaud C., et al. F-1-Adenosine triphosphatase displays properties characteristic of an antigen presentation molecule for V gamma 9V delta 2 T Cells. J.Immunol. 2010, 184:6920-6928.
104. Scotet E., Martinez L.O., Grant E., Barbaras R., Jeno P., Guiraud M., et al. Tumor recognition following Vgamma9Vdelta2 T cell receptor interactions with a surface F1-ATPase-related structure and apolipoprotein A-I. Immunity 2005, 22:71-80.
105. Vantourout P., Martinez L.O., Fabre A., Collet X., Champagne E. Ecto-F1-ATPase and MHC-class I close association on cell membranes. Mol. Immunol. 2008, 45:485-492.
106. Long E.O. Negative signaling by inhibitory receptors: the NK cell paradigm. Immunol. Rev. 2008, 224:70-84.
107. Zhang F.L., Luo L., Gustafson E., Palmer K., Qiao X., Fan X., et al. P2Y(13): identification and characterization of a novel Galphai-coupled ADP receptor from human and mouse. J.Pharmacol. Exp. Ther. 2002, 301:705-713.
108. Fumagalli M., Trincavelli L., Lecca D., Martini C., Ciana P., Abbracchio M.P. Cloning, pharmacological characterisation and distribution of the rat G-protein-coupled P2Y(13) receptor. Biochem. Pharmacol. 2004, 68:113-124.
109. Ben Addi A., Lefort A., Hua X., Libert F., Communi D., Ledent C., et al. Modulation of murine dendritic cell function by adenine nucleotides and adenosine: involvement of the A(2B) receptor. Eur. J. Immunol. 2008, 38:1610-1620.
110. Ben Addi A., Cammarata D., Conley P.B., Boeynaems J.-M., Robaye B. Role of the P2Y12 receptor in the modulation of murine dendritic cell function by ADP. J.Immunol. 2010, 185:5900-5906.
111. Yano S., Tsukimoto M., Harada H., Kojima S. Involvement of P2Y13 receptor in suppression of neuronal differentiation. Neurosci. Lett. 2012, 518:5-9.
112. Del Puerto A., Díaz-Hernández J.-I., Tapia M., Gomez-Villafuertes R., Benitez M.J., Zhang J., et al. Adenylate cyclase 5 coordinates the action of ADP, P2Y1, P2Y13 and ATP-gated P2X7 receptors on axonal elongation. J.Cell. Sci. 2012, 125:176-188.
113. Ortega F., Pérez-Sen R., Delicado E.G., Teresa Miras-Portugal M. ERK1/2 activation is involved in the neuroprotective action of P2Y13 and P2X7 receptors against glutamate excitotoxicity in cerebellar granule neurons. Neuropharmacology 2011, 61:1210-1221.
114. Espada S., Ortega F., Molina-Jijón E., Rojo A.I., Pérez-Sen R., Pedraza-Chaverri J., et al. The purinergic P2Y(13) receptor activates the Nrf2/HO-1 axis and protects against oxidative stress-induced neuronal death. Free Radic. Biol. Med. 2010, 49:416-426.
115. Malin S.A., Molliver D.C. Gi- and Gq-coupled ADP (P2Y) receptors act in opposition to modulate nociceptive signaling and inflammatory pain behavior. Mol. Pain 2010, 6:21.
116. Kobayashi K., Yamanaka H., Yanamoto F., Okubo M., Noguchi K. Multiple P2Y subtypes in spinal microglia are involved in neuropathic pain after peripheral nerve injury. Glia 2012, 60:1529-1539.
117. Voss U., Turesson M.F., Robaye B., Boeynaems J.-M., Olde B., Erlinge D., et al. The enteric nervous system of P2Y13 receptor null mice is resistant against high-fat-diet- and palmitic-acid-induced neuronal loss. Purinergic Signal 2014, 10:455-464.
118. Orriss I., Syberg S., Wang N., Robaye B., Gartland A., Jorgensen N., et al. Bone phenotypes of P2 receptor knockout mice. Front. Biosci. (Schol Ed) 2011, 3:1038-1046.
119. Wang N., Robaye B., Agrawal A., Skerry T.M., Boeynaems J.-M., Gartland A. Reduced bone turnover in mice lacking the P2Y(13) receptor of ADP. Mol. Endocrinol. 2012, 26:142-152.
120. Biver G., Wang N., Gartland A., Orriss I., Arnett T.R., Boeynaems J.-M., et al. Role of the P2Y13 receptor in the differentiation of bone marrow stromal cells into osteoblasts and adipocytes. Stem Cells 2013, 31:2747-2758.
121. Bartelt A., Beil F.T., Müller B., Koehne T., Yorgan T.A., Heine M., et al. Hepatic lipase is expressed by osteoblasts and modulates bone remodeling in obesity. Bone 2014, 62:90-98.
122. Lee H., Jun D.J., Suh B.C., Choi B.H., Lee J.H., Do M.S., et al. Dual roles of P2 purinergic receptors in insulin-stimulated leptin production and lipolysis in differentiated rat white adipocytes. J.Biol. Chem. 2005, 280:28556-28563.
123. Erlinge D., Burnstock G. P2 receptors in cardiovascular regulation and disease. Purinergic Signal 2008, 4:1-20.